Jim joined BBOT in December 2025 as Vice President of Clinical Pharmacology and DMPK, and brings more than two decades of experience in drug development. Prior to joining BBOT, Jim served as Vice President and Head of Clinical Pharmacology and DMPK at NiKang Therapeutics, Akeso Biopharma, and Clovis Oncology. In these roles, he led integrated clinical pharmacology and DMPK strategies from lead optimization through clinical development and regulatory submissions. Earlier in his career, he was a clinical pharmacologist at Amgen and Genentech, where he assumed roles of increasing responsibility. Jim has led and contributed to clinical pharmacology for multiple regulatory submissions, including those supporting six oncology drug approvals. He has also authored more than 40 peer-reviewed articles.

Jim received his PhD from the College of Pharmacy at The Ohio State University, an MS in Analytical Chemistry from the Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, and a BS in Pharmacy from Beijing Medical University.